Shopping Cart
- Remove All
![TargetMol](https://www.targetmol.com/storage/error/oops.webp)
Your shopping cart is currently empty
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $65 | In Stock | |
5 mg | $159 | In Stock | |
10 mg | $255 | In Stock | |
25 mg | $513 | In Stock | |
50 mg | $813 | In Stock | |
100 mg | $1,230 | In Stock | |
200 mg | $1,680 | In Stock | |
1 mL x 10 mM (in DMSO) | $176 | In Stock |
Description | Tegoprazan is a potassium-competitive acid blocker and is a potent, oral active, and highly selective inhibitor of gastric H+/K+-ATPase. That could control gastric acid secretion and motility (IC50: ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro). |
Targets&IC50 | H+, K+-ATPase:0.29-0.52 μM |
In vitro | Tegoprazan inhibits gastric H+/K+-ATPase in a potassium-competitive and reversible manner and it also inhibits porcine, canine, and human H+/K+-ATPase activity. Tegoprazan (3 μM) inhibits 86% of H+/K+-ATPase activity, whereas the inhibition is decreased to 34% after the dilution of Tegoprazan concentration to 0.15 μM [1]. |
In vivo | Tegoprazan (1.0-3.0 mg/kg, p.o.) reverses the pentagastrin-induced acidified gastric pH to the neutral range. Tegoprazan (1.0 mg/kg, p.o.) effectively and fully inhibits histamine-induced gastric acid secretion in dogs. Tegoprazan (3 mg/kg, p.o.) immediately evokes a gastric phase III contraction of the migrating motor complex in pentagastrin-treated dogs [1]. |
Molecular Weight | 387.38 |
Formula | C20H19F2N3O3 |
Cas No. | 942195-55-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
Solubility Information | DMSO: 22.5 mg/mL (58.08 mM) ![]() | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.